Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
RATIONALE: Schizophrenia remains among the most prevalent neuropsychiatric disorders, and current treatment options are accompanied by unwanted side effects. New treatments that better address core features of the disease with minimal side effects are needed. OBJECTIVES: As a new therapeutic approach, 1-(4-fluoro-phenyl)-4-((6bR, 10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one (ITI-007) is currently in human clinical trials for the treatment of schizophrenia. Here, we characterize the preclinical functional activity of ITI-007. RESULTS: ITI-007 is a potent 5-HT2A receptor ligand (K i = 0.5 nM) with strong affinity for dopamine (DA) D2 receptors (K i = 32 nM) and the serotonin transporter (SERT) (K i = 62 nM) but negligible binding to receptors (e.g., H1 histaminergic, 5-HT2C, and muscarinic) associated with cognitive and metabolic side effects of antipsychotic drugs. In vivo it is a 5-HT2A antagonist, blocking (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride (DOI)-induced headtwitch in mice with an inhibitory dose 50 (ID50) = 0.09 mg/kg, per oral (p.o.), and has dual properties at D2 receptors, acting as a postsynaptic D2 receptor antagonist to block D-amphetamine hydrochloride (D-AMPH) hyperlocomotion (ID50 = 0.95 mg/kg, p.o.), yet acting as a partial agonist at presynaptic striatal D2 receptors in assays measuring striatal DA neurotransmission. Further, in microdialysis studies, this compound significantly and preferentially enhances mesocortical DA release. At doses relevant for antipsychotic activity in rodents, ITI-007 has no demonstrable cataleptogenic activity. ITI-007 indirectly modulates glutamatergic neurotransmission by increasing phosphorylation of GluN2B-type N-methyl-D-aspartate (NMDA) receptors and preferentially increases phosphorylation of glycogen synthase kinase 3β (GSK-3β) in mesolimbic/mesocortical dopamine systems. CONCLUSION: The combination of in vitro and in vivo activities of this compound support its development for the treatment of schizophrenia and other psychiatric and neurologic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress
Berton, O., McClung, C. A., DiLeone, R. J., Krishnan, V., Renthal, W., Russo, S. J., Graham, D., Tsankova, N. M., Bolanos, C. A., Rios, M., et al. (2006) · Science · doi:10.1126/science.1120972 · Cited by 2,129
Self-citationDopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons
Chaudhury, D., Walsh, J. J., Friedman, A. K., Juarez, B., Ku, S. M., Koo, J. W., Ferguson, D., Tsai, H.-C., Pomeranz, L., Christoffel, D. J., et al. (2013) · Nature · doi:10.1038/nature11713 · Cited by 1,156 · cited 2×
“To the extent that mesolimbic/mesocortical dopamine tone is involved in mediating social stress (Chaudhury et al. 2013), however, the mesolimbic/mesocortical dopaminergic modulation displayed by ITI-007 may have additional benefit for antidepressant activity.”
BackgroundSelf-citationRoth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T., Yocca, F. D., & Molinoff, P. B. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.033175 · Cited by 922
Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum
Stoof, J. C., & Kebabian, J. W. (1981) · Nature · doi:10.1038/294366a0 · Cited by 917
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Rothman, R. B., Baumann, M. H., Savage, J. E., Rauser, L., McBride, A., Hufeisen, S. J., & Roth, B. L. (2000) · Circulation · doi:10.1161/01.cir.102.23.2836 · Cited by 722
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 714
Neurotransmitter Receptor and Transporter Binding Profile of Antidepressants and Their Metabolites
Owens, M. J., Morgan, W. N., Plott, S. J., & Nemeroff, C. B. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37161-7 · Cited by 676
Kane, J. M., Carson, W. H., Saha, A. R., McQuade, R. D., Ingenito, G. G., Zimbroff, D. L., & Ali, M. W. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0903 · Cited by 624
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Animal Models of Depression: Molecular Perspectives
Krishnan, V., & Nestler, E. J. (2011) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2010_108 · Cited by 528
Self-citationAkt/GSK3 Signaling in the Action of Psychotropic Drugs
Beaulieu, J.-M., Gainetdinov, R. R., & Caron, M. G. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145634 · Cited by 522
Owens, M. J., Knight, D. L., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01145-3 · Cited by 516
Ichikawa, J., Ishii, H., Bonaccorso, S., Fowler, W. L., O'Laughlin, I. A., & Meltzer, H. Y. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00154.x · Cited by 494
Nakazawa, T., Komai, S., Tezuka, T., Hisatsune, C., Umemori, H., Semba, K., Mishina, M., Manabe, T., & Yamamoto, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008085200 · Cited by 466
Possible Role of Valvular Serotonin 5-HT2B Receptors in the Cardiopathy Associated with Fenfluramine
Fitzgerald, L. W., Burn, T. C., Brown, B. S., Patterson, J. P., Corjay, M. H., Valentine, P. A., Sun, J.-H., Link, J. R., Abbaszade, I., Hollis, J. M., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26444-0 · Cited by 440
Sánchez, C., & Hyttel, J. (1999) · Cellular and Molecular Neurobiology · doi:10.1023/a:1006986824213 · Cited by 429
Moghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402
Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
Reynolds, G. P., & Kirk, S. L. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.010 · Cited by 401
Porter, R. H. P., Benwell, K. R., Lamb, H., Malcolm, C. S., Allen, N. H., Revell, D. F., Adams, D. R., & Sheardown, M. J. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702751 · Cited by 358
Wadenberg, M. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00261-5 · Cited by 256
RS-102221: A Novel High Affinity and Selective, 5-HT 2C Receptor Antagonist
BONHAUS, D. W., WEINHARDT, K. K., TAYLOR, M., DESOUZA, A., MCNEELEY, P. M., SZCZEPANSKI, K., FONTANA, D. J., TRINH, J., ROCHA, C. L., DAWSON, M. W., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00049-x · Cited by 251
Sutherland, C., & Cohen, P. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)80112-6 · Cited by 238
Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor
Pälvimäki, E. P., Majasuo, H., Laakso, A., Kuoppamäki, M., Syvälahti, E., Roth, B. L., & Hietala, J. (1996) · Psychopharmacology · doi:10.1007/bf02246453 · Cited by 197
Ichikawa, J., Li, Z., Dai, J., & Meltzer, H. Y. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03570-9 · Cited by 196
Conn, P. J., & Sanders-Bush, E. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90017-0 · Cited by 192
Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics
Li, X., Rosborough, K. M., Friedman, A. B., Zhu, W., & Roth, K. A. (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006547 · Cited by 191
Matsui-Sakata, A., Ohtani, H., & Sawada, Y. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.368 · Cited by 191
Goebel-Goody, S. M., Davies, K. D., Alvestad Linger, R. M., Freund, R. K., & Browning, M. D. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.006 · Cited by 188
Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia
Schwartz, T. L., Sachdeva, S., & Stahl, S. M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00195 · Cited by 187
Alimohamad, H., Rajakumar, N., Seah, Y.-H., & Rushlow, W. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.036 · Cited by 187
Laruelle, M. A., Frankle, W. G., Narendran, R., Kegeles, L. S., & Abi‐Dargham, A. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.017 · Cited by 171
Popa, D., Léna, C., Fabre, V., Prenat, C., Gingrich, J., Escourrou, P., Hamon, M., & Adrien, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1724-05.2005 · Cited by 170
Patel, J. K., Buckley, P. F., Woolson, S., Hamer, R. M., McEvoy, J. P., Perkins, D. O., Lieberman, J. A., & for the CAFE investigators (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.025 · Cited by 169
Auclair, A., Drouin, C., Cotecchia, S., Glowinski, J., & Tassin, J. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03805.x · Cited by 163 · cited 1×
“Although other aspects of its mechanism of action, such as 5-HT2A receptor antagonism, may indirectly contribute to these pharmacological effects (Auclair et al. 2004; Ichikawa et al. 2001), the absence of functional effects on multiple measures of striatal dopamine neurotransmission indicate that…”
BackgroundThe role of negative symptoms and cognitive dysfunction in schizophrenia outcome
Tamminga, C. A., Buchanan, R. W., & Gold, J. M. (1998) · International Clinical Psychopharmacology · doi:10.1097/00004850-199803003-00004 · Cited by 162
Gyertyán, I., Kiss, B., Sághy, K., Laszy, J., Szabó, G., Szabados, T., Gémesi, L. I., Pásztor, G., Zájer-Balázs, M., Kapás, M., et al. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.07.002 · Cited by 162
The emergin role of clozapine in the treatment of movement disorders
Factor, S. A., & Friedman, J. H. (1997) · Movement Disorders · doi:10.1002/mds.870120403 · Cited by 144
Marek, G. J., Martín‐Ruiz, R., Abo, A., & Artigas, F. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300762 · Cited by 131
Selective 5HT2A and 5HT6 Receptor Antagonists Promote Sleep in Rats
Morairty, S. R., Hedley, L., Flores, J., Martin, R., & Kilduff, T. S. (2008) · Sleep · doi:10.1093/sleep/31.1.34 · Cited by 117
Rygula, R., Abumaria, N., Havemann-Reinecke, U., Rüther, E., Hiemke, C., Zernig, G., Fuchs, E., & Flügge, G. (2008) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282fe8871 · Cited by 109
Targeting glutamate synapses in schizophrenia
Field, J. R., Walker, A. G., & Conn, P. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.08.004 · Cited by 105
Carty, N., Xu, J., Kurup, P., Brouillette, J., Goody, S. M. G., Austin, D. R., Yuan, P., Chen, G., Correa, P. R., Haroutunian, V., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.63 · Cited by 85
Harada, K., Wu, J., Haycock, J. W., & Goldstein, M. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67020629.x · Cited by 84
Gardell, L. R., Vanover, K. E., Pounds, L., Johnson, R. W., Barido, R., Anderson, G. T., Veinbergs, I., Dyssegaard, A., Brunmark, P., Tabatabaei, A., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121715 · Cited by 74
Self-citationRole of 5-HT2A receptor antagonists in the treatment of insomnia
Vanover, K. E., & Davis (2010) · Nature and Science of Sleep · doi:10.2147/nss.s6849 · Cited by 66
Self-citationFyn Is Required for Haloperidol-induced Catalepsy in Mice
Hattori, K., Uchino, S., Isosaka, T., Maekawa, M., Iyo, M., Sato, T., Kohsaka, S., Yagi, T., & Yuasa, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511608200 · Cited by 55
Ancoli‐Israel, S., Vanover, K. E., Weiner, D. M., Davis, R. E., & van Kammen, D. P. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2010.10.004 · Cited by 54
Self-citationNakai, S., Hirose, T., Uwahodo, Y., Imaoka, T., Okazaki, H., Miwa, T., Nakai, M., Yamada, S., Dunn, B., Burris, K. D., et al. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01857-0 · Cited by 43
Clark, D. T., Hjorth, S., & Carlsson, A. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90694-0 · Cited by 36
Jardemark, K. E., Marcus, M. M., Shahid, M., & Svensson, T. H. (2010) · Synapse · doi:10.1002/syn.20803 · Cited by 31
Harvey, M. L., Swallows, C. L., & Cooper, M. A. (2012) · Behavioral Neuroscience · doi:10.1037/a0029047 · Cited by 26
Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain
Zhu, H., OʼBrien, J., O'Callaghan, J. P., Miller, D. B., Qiang, Z., Rana, M., Tsui, T., Peng, Y., Tomesch, J., Hendrick, J. P., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.034 · Cited by 23
Self-citationBrennan, J. A., Graf, R., Grauer, S. M., Navarra, R. L., Pulicicchio, C. M., Hughes, Z. A., Lin, Q., Wantuch, C., Rosenzweig-Lipson, S. J., Pruthi, F., et al. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.157388 · Cited by 16
Cited by
Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391
Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial
Correll, C. U., Davis, R. E., Weingart, M., Saillard, J., O’Gorman, C., Kane, J. M., Lieberman, J. A., Tamminga, C. A., Mates, S., & Vanover, K. E. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.4379 · Cited by 288
Self-citationDopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
Self-citationITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial
Lieberman, J. A., Davis, R. E., Correll, C. U., Goff, D. C., Kane, J. M., Tamminga, C. A., Mates, S., & Vanover, K. E. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.026 · Cited by 261
Self-citationAhmed, M., Malik, M., Teselink, J., Lanctôt, K. L., & Herrmann, N. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00668-7 · Cited by 29
Metadata
- Authors
- Snyder, G. L., Vanover, K. E., Zhu, H., Miller, D. B., O’Callaghan, J. P., Tomesch, J., Li, P., Zhang, Q., Krishnan, V., Hendrick, J. P., Nestler, E. J., Davis, R. E., Wennogle, L. P., & Mates, S.
- Venue
- Psychopharmacology
- Published
- 2014-08-15
- Volume
- 232
- Issue
- 3
- Pages
- 605-621
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1976520993
- Cited by
- 289
- References
- 63
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.